Last reviewed 2026-04-23 · How we verify

HMI-115

HMI-115 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.

HMI-115 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).

At a glance

Mechanism of action

HMI-115 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing the suppressive signal that tumors use to evade the immune system. By blocking the PD-L1/PD-1 axis, the drug restores T-cell activation and proliferation, enabling the immune system to recognize and attack cancer cells more effectively.

Approved indications

• Non-small cell lung cancer
• Other solid tumors (under investigation)

Common side effects

• Fatigue
• Decreased appetite
• Immune-related adverse events
• Infusion-related reactions

Key clinical trials

• A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain (PHASE2)
• Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain (PHASE3)
• A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia (PHASE2)
• To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HMI-115 CI brief — competitive landscape report
• HMI-115 updates RSS · CI watch RSS
• Hope Medicine (Nanjing) Co., Ltd portfolio CI